Myeloid-derived suppressor cells as effectors of immune suppression in cancer

International Journal of Cancer

Volumn 139, Issue 9, 2016, Pages 1915-1926

  Pyzer, Athalia Rachel ^a   Cole, Leandra ^a   Rosenblatt, Jacalyn ^a   Avigan, David E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cancer; immunology; myeloid; myeloid derived suppressor cell

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTINEOPLASTIC AGENT; BARDOXOLONE METHYL; BEVACIZUMAB; CELECOXIB; CURCUMIN; FLUOROURACIL; GAMMA INTERFERON ANTIBODY; GEMCITABINE; GR 1 MONOCLONAL ANTIBODY; ICARIIN; IMMUNOSUPPRESSIVE AGENT; MICRORNA; N HYDROXY ARGININE; QW 2580; RETINOIC ACID; SILDENAFIL; SUNITINIB; TADALAFIL; TASQUINIMOD; UNCLASSIFIED DRUG; VEMURAFENIB; WITHAFERIN A; ZOLEDRONIC ACID;

B CELL LYMPHOMA; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID DERIVED SUPPRESSOR CELL; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 84983036426     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30232     Document Type: Review

References (218)

1. Duwe AK, Singhal SK. The immunoregulatory role of bone marrow. I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow. Cell Immunol 1979;43:362–71.
2. Bronte V, Wang M, Overwijk WW, et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998;161:5313–20.
3. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000;165:779–85.
4. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150–66.
5. Watson GA, Fu YX, Lopez DM. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol 1991;49:126–38.
6. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002;168:689–95.
7. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989–99.
8. Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003;170:270–8.
9. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000;96:3838–46.
10. Mielcarek M, Martin PJ, Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997;89:1629–34.
11. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
12. Singh RK, Varney ML, Buyukberber S, et al. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer Res 1999;59:3107–11.
13. Laoui D, Van Overmeire E, Movahedi K, et al. Mononuclear phagocyte heterogeneity in cancer: Different subsets and activation states reaching out at the tumor site. Immunobiology 2011;216:1192–202.
14. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425.
15. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol 2012;12:253–68.
16. Mucha J, Majchrzak K, Taciak B, et al. MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. PLoS One [Internet] 2014;9:e103249.
17. Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front Immunol [Internet] 2015; 6:523.
18. Zhang G, Huang H, Zhu Y, et al. A novel subset of B7-H3(+)CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology [Internet] 2015;4:e977164.
19. Li Z-L, Ye S-B, OuYang L-Y, et al. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology [Internet] 2015;4:e1044712.
20. Huang H, Zhang G, Li G, et al. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumour Biol [Internet]. 2015;15(4):425–32
21. Jeanbart L, Kourtis IC, van der Vlies AJ, et al. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. Cancer Immunol Immunother [Internet] 2015;64:1033–46.
22. Sheng Sow H, Mattarollo SR. Combining low-dose or metronomic chemotherapy with anticancer vaccines: a therapeutic opportunity for lymphomas. Oncoimmunology [Internet] 2013;2:e27058.
23. Nicholson LB, Raveney BJE, Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr Mol Med 2009;9:23–9.
24. Van Ginderachter JA, Beschin A, Baetselier P, et al. Myeloid-derived suppressor cells in parasitic infections. Eur. J. Immunol 2010; 40:2976–85.
25. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol 2011; 11:789–93.
26. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 2013;123:4595–611.
27. Solito S, Falisi E, Diaz-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011;118:2254–65.
28. Youn J-I, Kumar V, Collazo M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol [Internet] 2013;14:211–20.
29. De Vlaeminck Y, González-Rascón A, Goyvaerts C, et al. Cancer-associated myeloid regulatory cells. Front Immunol [Internet] 2016;7:113.
30. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553–60.
31. George S, Rayman P, Biswas S, et al.and JHF. Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (Pts). In: ASCO. 2008.
32. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562–8.
33. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235–49.
34. Feng P-H, Lee K-Y, Chang Y-L, et al. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med [Internet] 2012;186:1025–36.
35. Wang L, Chang EWY, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol [Internet] 2013;190:794–804.
36. Zhao F, Hoechst B, Duffy A, et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 2012;136:176–83.
37. Qin H, Lerman B, Sakamaki I, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med [Internet] 2014;20:676–81.
38. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656–61.
39. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 2013;57:172–84.
40. Porembka MR, Mitchem JB, Belt BA, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother 2012;61:1373–85.
41. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49–59.
42. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000;164:2214–20.
43. Draghiciu O, Nijman HW, Hoogeboom BN, et al. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology [Internet] 2015;4:e989764.
44. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546–53.
45. Vuk-Pavlović S, Bulur PA, Lin Y, et al. Immunosuppressive CD14+HLA-DRlow/− monocytes in prostate cancer. Prostate 2010;70:443–55.
46. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 2008;135:234–43.
47. Weed DT, Vella JL, Reis IM, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res [Internet] 2015;21:39–48.
48. Napolitano M, D'Alterio C, Cardone E, et al. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget [Internet] 2015;6:8261–70.
49. Aliper AM, Frieden-Korovkina VP, Buzdin A, et al. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget [Internet] 2014;5:11345–53.
50. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol [Internet] 2015;74:390–400.
51. Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res [Internet] 2014;2014:879897.
52. Liu CY, Wang YM, Wang CL, et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33 + myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35–45.
53. Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011;117:872–81.
54. Sato Y, Shimizu K, Shinga J, et al. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. Oncoimmunology [Internet] 2015;4:e995541.
55. Romano A, Parrinello NL, Vetro C, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol [Internet] 2015;168:689–700.
56. Liu J, Zhou Y, Huang Q, et al. CD14(+)HLA-DR(low/-) expression: a novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett [Internet] 2015;9:1167–72.
57. Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014;124:750–60.
58. De Veirman K, Van Ginderachter JA, Lub S, et al. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget [Internet] 2015;6:10532–47.
59. G¨or¨gun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121:2975–87.
60. Ramachandran IR, Martner A, Pisklakova A, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol [Internet] 2013;190:3815–23.
61. Brimnes MK, Vangsted AJ, Knudsen LM, et al. Increased level of both CD4+FOXP3+ Regulatory t Cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010;72:540–7.
62. Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood [Internet] 2013;121:2975–87.
63. Christiansson L, Söderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. e55818. PLoS One 2013;8.
64. Miner S, Ito S, Tanimoto K, Hensel N, et al. Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. In: ASH. 2013.
65. Lechner MG, Megiel C, Russell SM, et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011;9:90.
66. Dufait I, Schwarze JK, Liechtenstein T, et al. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget [Internet] 2015;6:12369–82.
67. Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822–35.
68. Bronte V, Chappell DB, Apolloni E, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728–37.
69. Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat [Internet] 2010;123:39–49. [cited 2016 Apr 5].
70. Liechtenstein T, Perez-Janices N, Gato M, et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget [Internet] 2014;5:7843–57. [cited 2016 Apr 30].
71. Zhou Z, French DL, Ma G, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells [Internet] 2010;28:620–32.
72. Waight JD, Hu Q, Miller A, et al. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. e27690. PLoS One 2011;6.
73. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008;111:219–28.
74. Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461–71.
75. Chen M-F, Kuan F-C, Yen T-C, et al. IL-6-stimulated CD11b+ CD14+ HLA-DR-myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget [Internet] 2014;5:8716–28.
76. Elkabets M, Ribeiro VSG, Dinarello CA, et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010;40:3347–57.
77. Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012;122:4094–104.
78. Villanueva MT. Microenvironment: small containers, important cargo. Nat Rev Cancer [Internet] 2014;14:764.
79. Balaj L, Atai NA, Chen W, et al. Heparin affinity purification of extracellular vesicles. Sci Rep [Internet] 2015;5:10266.
80. Webber J, Yeung V, Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol [Internet] 2015;40:27–34. [25662446]
81. Xiang X, Poliakov A, Liu C, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009;124:2621–33.
82. Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res [Internet] 2006;66:9290 [cited 2016 Mar 20];:– http://www.ncbi.nlm.nih.gov/pubmed/16982774
83. Rébé C, Végran F, Berger H, et al. STAT3 activation: a key factor in tumor immunoescape. JAK-STAT [Internet] 2013;2:e23010.
84. Miner S, Ito S, Tanimoto K, Hensel N, Barrett J. Myeloid Leukemias directly suppress T cell proliferation through STAT3 and Arginase pathways. In: ASH 2013. New Orleans: 2013.
85. Trikha P, Carson WE. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta —Rev Cancer 2014;1846:55–65.
86. Dufait I, Van Valckenborgh E, Menu E, et al. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget [Internet] 2016. http://www.ncbi.nlm.nih.gov/pubmed/27029037
87. Cohen PA, Ko JS, Storkus WJ, et al. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest [Internet] 2012;41:680–710.
88. Yu S, Liu C, Su K, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol [Internet] 2007;178:6867–75.
89. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest [Internet] 2013;123:1580–9.
90. Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367–77.
91. Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69:2506–13.
92. Wu L, Du H, Li Y, et al. Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 2011;179:2131–41.
93. Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 + T cells from patients with GI malignancy. Cancer Immunol Immunother 2011;60:1269–79.
94. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005;174:636–45.
95. Wang X, Chang X, Zhuo G, et al. Twist and miR-34a are involved in the generation of tumor-educated myeloid-derived suppressor cells. Int J Mol Sci 2013;14:20459–77.
96. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11–22.
97. Behre G, Singh SM, Liu H, et al. Ras signaling enhances the activity of C/EBPα to induce granulocytic differentiation by phosphorylation of serine 248. J Biol Chem 2002;277:26293–9.
98. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518–27.
99. Enioutina EY, Bareyan D, Daynes RA. A role for immature myeloid cells in immune senescence. J Immunol 2011;186:697–707.
100. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184–92.
101. Ghansah T. A novel strategy for modulation of MDSC to enhance cancer immunotherapy. Oncoimmunology 2012;1:984–5.
102. Li L, Zhang J, Diao W, et al. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol [Internet] 2014;192:1034–43.
103. Chen S, Wang L, Fan J, et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res [Internet] 2015;75:519–31.
104. Kim S, Song JH, Kim S, et al. Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration. Oncotarget [Internet] 2016;7:11094–112.
105. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci [Internet] 2012;33:207–14.
106. Zhao C, Zhang Q, Yu T, et al. Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling. J Bone Oncol [Internet] 2016;5:22–9.
107. Syu J-P, Chi J-T, Kung H-N. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget [Internet] 2016;7(12):14659–72.
108. Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science (80-) [Internet] 2016;352:175–80.
109. Sceneay J, Parker BS, Smyth MJ, et al. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology [Internet] 2013;2:e22355.
110. Duechler M, Peczek L, Zuk K, et al. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. Immunobiology [Internet] 2014;219:158–65.
111. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med [Internet] 2014;211:781–90.
112. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology [Internet] 2014;143:512–9.
113. Corzo CA, Condamine T, Lu L, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med [Internet] 2010;207:2439–53.
114. Noman MZ, Janji B, Hu S, et al. Tumor-psromoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210. Cancer Res [Internet] 2015;75:3771–87.
115. Mikysková R, Indrová M, Vlková V, et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol [Internet] 2014. http://www.ncbi.nlm.nih.gov/pubmed/24389335
116. Sevko A, Sade-Feldman M, Kanterman J, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol [Internet] 2013;133:1610–9.
117. Ding Z-C, Lu X, Yu M, et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res [Internet] 2014;74:3441–53
118. Dang Y, Wagner WM, Gad E, et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res [Internet] 2012;18:3122–31.
119. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907–16.
120. Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1–17.
121. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839–49.
122. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007;109:1568–73.
123. Oberlies J, Watzl C, Giese T, et al. Regulation of NK cell function by human granulocyte arginase. J Immunol 2009;182:5259–67.
124. Popovic PJ, Zeh HJ, Ochoa JB. Arginine and immunity. J Nutr 2007;137:1681S–1686S.
125. Bingisser RM, Tilbrook PA, Holt PG, et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998;160:5729–34.
126. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des 2004;10:893–8.
127. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase denitrosylation. Science 1999;284:651–4.
128. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61:4756–60.
129. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007;13:828–35.
130. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641–54.
131. Youn J-I, Collazo M, Shalova IN, et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012;91:167–81.
132. Youn J-I, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40:2969–75.
133. Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P,L, Blanc K. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2012;27(2):377–88.
134. Sakuishi K, Jayaraman P, Behar SM, et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011;32:345–9.
135. Liechtenstein T, Perez-Janices N, Blanco-Luquin I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology [Internet] 2016;3:e945378.
136. Chavan R, Salvador D, Gustafson MP, et al. Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer Immunol Res [Internet] 2014;2:241–8.
137. Young MR, Wright MA, Matthews JP, et al. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol 1996;156:1916–22.
138. Terabe M, Matsui S, Park J-M, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741–52.
139. Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol [Internet] 2012;188:5500–10.
140. Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009;182:240–9.
141. 2 catabolism in myeloid cells. J Leukoc Biol 2010;88:839–48.
142. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005;202:931–9.
143. Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009;182:3801–8.
144. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14:408–19.
145. Yu J, Wang Y, Yan F, et al. Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer. J Immunol [Internet] 2014;193(5):2574–86.
146. Nagaraj S, Schrum AG, Cho H-I, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106–16.
147. Gabrilovich DI, Velders MP, Sotomayor EM, et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001;166:5398–406.
148. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010;120:457–71.
149. Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16:4583–94.
150. Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439–49.
151. Nagaraj S, Nelson A, Youn J.-I, et al. Antigen-specific CD4+ T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC Class II signaling. Cancer Res 2012;72:928–38.
152. Chan LLY, Cheung BKW, Li JCB, et al. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol 2010;88:303–11.
153. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123–31.
154. Adeegbe D, Serafini P, Bronte V, et al. In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice. Cell Transplant 2011;20:941–54.
155. Hoechst B, Gamrekelashvili J, Manns MP, et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011;117:6532–41.
156. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99–108.
157. Hoechst B, Voigtlaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799–807.
158. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007;67:4507–13.
159. Narita Y, Wakita D, Ohkur T, et al. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res [Internet] 2009;30:7–15.
160. Hu C-E, Gan J, Zhang R-D, et al. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol 2011;46:156–64.
161. Poschke I, Mao Y, Adamson L, et al. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012;61:827–38.
162. Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977–83.
163. Kumar V, Cheng P, Condamine T, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity [Internet] 2016;44:303–15.
164. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res [Internet] 2013;73:2782–94
165. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res [Internet] 2014;74:5057–69.
166. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res [Internet] 2011;71:2664–74.
167. Obermajer N, Muthuswamy R, Odunsi K, et al. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res [Internet] 2011;71:7463–70
168. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713–21.
169. Bill MA, Fuchs JR, Li C, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010;9:165.
170. Lu P, Yu B, Xu J. Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother Radiopharm 2012;27:495–503.
171. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) [Internet] 2012;5:205–15. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3273601&tool=pmcentrez&rendertype=abstract
172. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70:3526–36.
173. Kodera Y, Katanasaka Y, Kitamura Y, et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 2011;13:R66.
174. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674–82.
175. Raymond E, Dalgleish A, Damber JE, et al. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 2014;73:1–8.
176. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013;133:1653–63.
177. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006;66:9299–307.
178. Nefedova Y, Fishman M, Sherman S, et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007;67:11021–8.
179. Waldron TJ, Quatromoni JG, Karakasheva TA, et al. Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology [Internet] 2013;2:e24117. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3654606&tool=pmcentrez&rendertype=abstract
180. Testa U, Masciulli R, Tritarelli E, et al. Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol 1993;150:2418–30.
181. Zhou J, Wu J, Chen X, et al. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol 2011;11:887–95.
182. Wu H, Tao N, Liu X, et al. Polysaccharide from lentinus edodes inhibits the immunosuppressive function of myeloid-derived suppressor cells. PLoS One 2012;7:e51751.
183. Kusmartsev S, Eruslanov E, Kübler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: Link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008;181:346–53.
184. Movahedi K, Guilliams M, Van Den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell suppressive activity. Blood 2008;111:4233–44.
185. Roelofs AJ, Ebetino FH, Reszka AA, et al. Bisphosphonates: mechanisms of action. In: Principles of bone biology, two-volume set. 2008. 1737–67.
186. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand. Cell 2002;109:625–37.
187. Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438–46.
188. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691–702.
189. De Santo C, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005;102:4185–90.
190. Gao P, Zhang H, Dinavahi R, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007;12:230–8.
191. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol [Internet] 2012;188:1592–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3273593&tool=pmcentrez&rendertype=abstract
192. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892–9.
193. Kawarada Y, Ganss R, Garbi N, et al. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247–53.
194. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357–69.
195. Konopleva M, Zhang W, Shi Y-X, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2006;5:317–28.
196. Muralikrishnan G, Dinda AK, Shakeel F. Immunomodulatory effects of Withania somnifera on azoxymethane induced experimental colon cancer in mice. Immunol Invest 2010;39:688–98.
197. Sinha P, Ostrand-Rosenberg S. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunol Immunother 2013;62:1663–73.
198. Seung LP, Rowley DA, Dubey P, et al. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995;92:6254–8.
199. Roth F, De La Fuente AC, Vella JL, et al. Aptamer-mediated blockade of IL4R?? triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012;72:1373–83.
200. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777–90.
201. Le HK, Graham L, Cha E, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009;9:900–9.
202. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052–61.
203. Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med [Internet] 2013;19:57–64. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23202296
204. Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007;67:7477–86.
205. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441–9.
206. Bose A, Taylor JL, Alber S, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129:2158–70.
207. Ozao-Choy J, Ge M, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–22.
208. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625–35.
209. Highfill S, Smith J, Long A, et al. Neutralization of murine myeloid suppressor cells enhances the efficacy of GD2-specific CAR T cells directed against human sarcoma in a xenograft model (VAC11P.1010). J Immunol [Internet] 2014;192:205.11. Available at: http://www.jimmunol.org/content/192/1_Supplement/205.11.abstract
210. Burga RA, Thorn M, Point GR, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother [Internet] 2015;64:817–29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25850344
211. John LB, Devaud C, Duong CPM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013;19:5636–46.
212. Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell [Internet] 2015;28:285–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26373277
213. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010;16:5539–47.
214. Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother [Internet] 2013;62:909–18. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23589106
215. A Phase IINational Institute of Dental and Craniofacial Research (NIDCR) Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016- [2016.07.06]. Available at: https://clinicaltrials.gov/ct2/show/NCT01697800?term=tadalafil+prevnar&rank=2, NLM Identifier: NCT01697800.
216. Khan IN, Al-Karim S, Bora RS, et al. Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov Today [Internet] 2015;20:1205–1216. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26143148
217. Grosicki S, Holowiecki J, Kuliczkowski K, et al. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients; a retrospective, multicenter Polish Adult Leukemia Group study. Am J Hematol [Internet] 2015;90:904–909. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26149802
218. Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol 2010;37:430–9.